Accessibility settings

JMIRx Med

PubMed-indexed overlay journal for preprints with post-review manuscript marketplace (What is JMIRx?).

Editor-in-Chief:

Fuqing Wu, PhD, The University of Texas Health Science Center at Houston, School of Public Health, Texas, USA


JMIRx Med (ISSN 2563-6316), which has been accepted for indexing in PubMed and PubMed Central, is an innovative overlay journal to  MedRxiv and JMIR Preprints (other preprint servers are invited to join). JMIRx peer-reviews preprints and publishes their revised "version of record" with peer-review reports across a broad range of medical, clinical and related health sciences. Unlike the majority of JMIR journals, papers published in this journal do not require a digital health focus - in fact, most papers we published in the first months of the journal were related to COVID19, but we publish all research that qualifies for preprinting on MedRxiv

Conceived to address the urgent need to make highly relevant scientific information available as early as possible without losing the quality of the peer-reviewed process, this innovative new journal is the first in a new series of “superjournals”. Superjournals (a type of "overlay" journal) sit on top of preprint servers (JMIRx-Med serves MedRxiv and JMIR Preprints), offering peer-review and everything else a traditional scholarly journal does. Our goal is to rapidly peer review and publish a paper. All JMIRx Med papers must have originated as a preprint. 

All JMIRx Med papers are rigorously peer-reviewed, copyedited and XML-tagged. Accepted papers are published along with the related Peer Review Reports and Author Responses to Peer Review Reports, providing an additional layer of transparency to the scholarly publishing process. 

There is no Article Processing Fee directly paid by authors for this journal. JMIRx Med is envisioned as a diamond open access and Plan-P compliant journal, which enables Plan P member universities/institutions and funders to subsidize peer review of preprints and publishing in JMIRx Med. Individual PI-led labs, departments and universities can become institutional members, guaranteeing unlimited peer-review of preprints.

If you are not affiliated with a Plan P member organization, we encourage you to provide Plan P membership details to your administrator or sign up for a Principal Investigator (PI) level membership. Further details provided here.

For a limited time only, authors who opt-in during submission to receive PREreview or PeerRef community peer review for their preprint or refer us to their department head/librarian/funder contact will receive a membership-waiver and may publish the preprint in JMIRx Med at no cost to the author. Referral form provided here.

To submit a preprint to JMIRx, authors can self-nominate their existing preprints for publication (which is the equivalent to a traditional journal submission), using the minimalistic JMIRx-Med submission form that essentially only points to the preprint (the preprint needs to be unpublished and should not be under consideration by a journal).

 

Preprints that have already been peer-reviewed by third-party Plan P accredited peer-review services such as PREreview and PeerRef do not require further peer-review (at the editors' discretion). In the submission process, you can nominate your preprint for a PREreview journal club, which can be used in lieu of traditional peer-review.

 

For more details on other submission pathways (including for papers not in MedRxiv) and peer-review options see How to submit to a JMIRx journal.

For more information on JMIRx please also see our Knowledge Base article "What is JMIRx?".  

 

 

Recent Articles

Two professionals in conversation at a networking event, holding smartphones.
Viewpoints

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use published the estimand framework in 2019. The estimand framework aims to clearly define a treatment effect for a clinical question through construction of estimands, and it has been widely applied in clinical trials in the pharmaceutical industry. The estimand framework proposes 5 attributes for an estimand: treatments, variables, target populations, population-level summaries, and intercurrent events. It also proposes the treatment policy strategy, the hypothetical strategy, the composite variable strategy, the while on treatment strategy, and the principal stratum strategy to handle intercurrent events. When people give clear definitions for these 5 attributes, they clearly define an estimand that represents a treatment effect. From a statistical perspective, a genuine or causal treatment effect is defined through a causal inference framework. This article aims to interpret the estimand framework using a causal inference framework and help researchers understand the differences between estimands and causal treatment effects. From a causal inference framework based on potential outcomes, an individual treatment effect (ITE) is defined by comparison of individual potential outcomes with experimental or control treatments, and the average treatment effect (ATE) of the experimental treatment versus the control treatment is defined as an average of all ITEs. The statistical presentation of the ATE is not equivalent to an estimand. It has the same treatments, variables, target populations, and population-level summaries as an estimand, but intercurrent events are not part of it. Intercurrent events modify the statistical presentation of the ATE through treatments, variables, and target populations, whose impact can be controlled by intercurrent event strategies. I propose that the estimand attributes can be mapped onto the statistical presentation of the ATE, and that intercurrent events act as mediation mechanisms in the attribute mapping process, which provides a novel way to incorporate the causal inference framework into the estimand framework. If the estimand framework is combined with a causal inference framework, it will gain a stronger theoretical foundation. The interpretation of the estimand framework from a causal inference perspective is useful for both industrial and academic clinical trials. Observational studies may also find useful information on causal inference theories in this article.

Doctor reviews DeepSeek R1 AI medical software on laptop, patient case summary on screen
#xHealthInformatics

Generative artificial intelligence models, especially reasoning large language models (LLMs), are gaining adoption in health care for diagnostic decision support and medical education. DeepSeek R1 is a reasoning LLM that generates extended chain-of-thought explanations to make its decision-making process more explicit. Traditional medical benchmarks often lack complexity and authenticity, motivating the adoption of scenario-rich datasets, such as the Massive Multitask Language Understanding Pro (MMLU-Pro) professional medicine subset, which provides multispecialty clinical vignettes for reasoning-centric evaluation.

Preprints Open for Peer Review

There are no preprints available for open peer-review at this time. Please check back later.

We are working in partnership with